1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Cystic Fibrosis Foundation Screening Improvement Program (SIP) - CF-GENES-II: Improving Genetic Counseling Access for Caregivers of Infants with Cystic Fibrosis Newborn Screen-Positive, Inconclusive Diagnosis in New York State is sponsored by Cystic Fibrosis Foundation. This grant aims to improve genetic counseling access for caregivers of infants in New York State with cystic fibrosis newborn screen-positive, inconclusive diagnosis.
Get alerted about grants like this
Get emailed when new opportunities from “Cystic Fibrosis Foundation” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Cystic Fibrosis Foundation Funds Collaborative Newborn Screening Project at the Wadsworth Center | New York State Department of Health, Wadsworth Center Cystic Fibrosis Foundation Funds Collaborative Newborn Screening Project at the Wadsworth Center The Newborn Screening Program at the Wadsworth Center has been awarded a two-year Cystic Fibrosis Foundation Screening Improvement Program (SIP) grant titled CF-GENES-II: Improving Genetic Counseling Access for Caregivers of Infants with Cystic Fibrosis Newborn Screen-Positive, Inconclusive Diagnosis in New York State.
The Wadsworth Center screens every infant born in New York State for cystic fibrosis (CF). Infants with positive screening results are referred to one of the state’s specialty care centers for diagnostic testing, clinical evaluation, treatment, and follow-up. Cystic fibrosis is a chronic, progressive genetic disorder affecting the lungs, pancreas, and other organs.
Common symptoms include failure to thrive, recurrent respiratory infections, wheezing, persistent cough, chronic sinus disease, and male infertility. Early detection through newborn screening enables timely intervention and improves long-term health outcomes.
Although genetic counseling is recommended for all families of screen-positive infants, the Newborn Screening Program identified substantial variability in counseling access across the state.
The new SIP award aims to increase the proportion of caregivers who receive genetic counseling following a positive CF newborn screening result or a designation of CFTR -related metabolic syndrome/cystic fibrosis screen-positive, inconclusive diagnosis (CRMS/CFSPID). These infants often present with complex or uncertain prognoses, making high-quality genetic counseling essential.
Through this project, caregivers of screen-positive infants will be offered consultation with a trained genetic counselor as part of standard care. The team will also assess and address factors that influence access to counseling services statewide. The project is funded by the Cystic Fibrosis Foundation and involves collaboration with 10 cystic fibrosis specialty care centers across New York State.
The principal investigator is Dr. Denise Kay, PhD, Director of the Newborn Screening Program. Newborn Screening Program
According to the current listing, eligibility includes: The Newborn Screening Program at the Wadsworth Center (New York State Department of Health) was awarded this grant. The project involves collaboration with 10 cystic fibrosis specialty care centers across New York State. Confirm the full requirements in the official notice before applying.
Cystic Fibrosis Foundation Screening Improvement Program (SIP) - CF-GENES-II: Improving Genetic Counseling Access for Caregivers of Infants with Cystic Fibrosis Newborn Screen-Positive, Inconclusive Diagnosis in New York State is funded by Cystic Fibrosis Foundation. Verify program details on the funder's official page before applying.
This opportunity targets applicants in New York. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.